PharmDelve

Delveinsight

Aug 16, 2016

Pharm Delve Cognizance

Unleashing the Potential: CD38 Directed Therapies Revolutionize Multiple Myeloma Treatment

Articles

Sep 24, 2024

Roche’s HER2-Positive Breast Cancer Treatment Franchise

Articles

Aug 13, 2024

BMS Vs. Janssen: Which Company Will Dominate The Multiple Myeloma Treatment Market This Decade?

Articles

Jul 25, 2024

Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes

Articles

Jul 24, 2024

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper